Explore the vast range of titles available.

This project investigates the implications of technology on identity in embodied performance, exploring the interrelationship of & between identities in performance practices & considering how identity is formed, de-formed, blurred & celebrated within diverse approaches to technological performance practice.

In this article, it is my intention to examine and compare aesthetic and neuroaesthetic theorisation in order to provide interpretive strategies that would be capable of addressing sophisticated technological art practices. In doing so, I will provide a study of two mutually enhancing approaches to this analysis - namely, the writings and aesthetic theorisation of Maurice Merleau-Ponty and a neuroaesthetic approach linking performance and art practices to neuroscientific research in order to provide some understanding of the biolog ical underpinnings of aesthetic experience. It is my belief that these diverse approaches have much to contribute to interpreting such developments. Due to the vast amount of research undertaken in this area, visual perception is central (though not exclusive) to a biologically related approach. The general direction of such research illuminates the problem as summarised by Francis Crick: 'It is difficult for many people to accept that what they see is a symbolic interpretation of the world - it all seems so much like \"the real thing\"'.

This book explores technologies related to bodily interaction and creativity from a multi-disciplinary perspective. By taking such an approach, the collection offers a comprehensive view of digital technology research that both extends our notions of the body and creativity through a digital lens, and informs of the role of technology in practices central to the arts and humanities. Crucially, Digital Bodies foregrounds creativity, the interrogation of technologies and the notion of embodiment within the various disciplines of art, design, performance and social science. In doing so, it explores a potential or virtual new sense of the embodied self. This book will appeal to academics, practitioners and those with an interest in not only how digital technologies affect the body, but also how they can enhance human creativity.

In this article, it is my intention to examine and compare aesthetic and neuroaesthetic theorisation in order to provide interpretive strategies that would be capable of addressing sophisticated technological art practices. In doing so, I will provide a study of two mutually enhancing approaches to this analysis - namely, the writings and aesthetic theorisation of Maurice Merleau-Ponty and a neuroaesthetic approach linking performance and art practices to neuroscientific research in order to provide some understanding of the biolog ical underpinnings of aesthetic experience. It is my belief that these diverse approaches have much to contribute to interpreting such developments. Due to the vast amount of research undertaken in this area, visual perception is central (though not exclusive) to a biologically related approach. The general direction of such research illuminates the problem as summarised by Francis Crick: 'It is difficult for many people to accept that what they see is a symbolic interpretation of the world - it all seems so much like \"the real thing\"'.

Part artificial intelligence, part 3D animation, Jeremiah interacts emotionally with spectators and other performers in a performance of the interface between humans and technology. [PUBLICATION ABSTRACT]

Neweys book is a politicized cultural history that aims to make visible those previously invisible women writers who have been excluded, not just from theatre practice but also from theatre history, by a pincer movement of ideological, economic, historiographical, and critical practices in both the contemporary nineteenth-century context and today. The fourteen chapters of Performance and Tech -nology are a tour-de-force of digital performance practices a well-balanced mixture of in-depth literature review, useful practical examples, and fresh ideas. The central theme of the narrative remains the exploration of the notion of the body in terms of new technologies mainly within choreographic practices, including kinetic interplay between dance and cinema (John Cook), telematic dance games within online multi-player environments (Johannes Birringer), and practical use of motion-tracking technology in dance performances (Robert Wechsler, Gretchen Schiller).

Introduction: Background to metabolomics Metabolomics is the comprehensive study of the metabolome, the repertoire of biochemicals (or small molecules) present in cells, tissues, and body fluids. The study of metabolism at the global or “-omics” level is a rapidly growing field that has the potential to have a profound impact upon medical practice. At the center of metabolomics, is the concept that a person’s metabolic state provides a close representation of that individual’s overall health status. This metabolic state reflects what has been encoded by the genome, and modified by diet, environmental factors, and the gut microbiome. The metabolic profile provides a quantifiable readout of biochemical state from normal physiology to diverse pathophysiologies in a manner that is often not obvious from gene expression analyses. Today, clinicians capture only a very small part of the information contained in the metabolome, as they routinely measure only a narrow set of blood chemistry analytes to assess health and disease states. Examples include measuring glucose to monitor diabetes, measuring cholesterol and high density lipoprotein/low density lipoprotein ratio to assess cardiovascular health, BUN and creatinine for renal disorders, and measuring a panel of metabolites to diagnose potential inborn errors of metabolism in neonates. Objectives of White Paper—expected treatment outcomes and metabolomics enabling tool for precision medicine We anticipate that the narrow range of chemical analyses in current use by the medical community today will be replaced in the future by analyses that reveal a far more comprehensive metabolic signature. This signature is expected to describe global biochemical aberrations that reflect patterns of variance in states of wellness, more accurately describe specific diseases and their progression, and greatly aid in differential diagnosis. Such future metabolic signatures will: (1) provide predictive, prognostic, diagnostic, and surrogate markers of diverse disease states; (2) inform on underlying molecular mechanisms of diseases; (3) allow for sub-classification of diseases, and stratification of patients based on metabolic pathways impacted; (4) reveal biomarkers for drug response phenotypes, providing an effective means to predict variation in a subject’s response to treatment (pharmacometabolomics); (5) define a metabotype for each specific genotype, offering a functional read-out for genetic variants: (6) provide a means to monitor response and recurrence of diseases, such as cancers: (7) describe the molecular landscape in human performance applications and extreme environments. Importantly, sophisticated metabolomic analytical platforms and informatics tools have recently been developed that make it possible to measure thousands of metabolites in blood, other body fluids, and tissues. Such tools also enable more robust analysis of response to treatment. New insights have been gained about mechanisms of diseases, including neuropsychiatric disorders, cardiovascular disease, cancers, diabetes and a range of pathologies. A series of ground breaking studies supported by National Institute of Health (NIH) through the Pharmacometabolomics Research Network and its partnership with the Pharmacogenomics Research Network illustrate how a patient’s metabotype at baseline, prior to treatment, during treatment, and post-treatment, can inform about treatment outcomes and variations in responsiveness to drugs (e.g., statins, antidepressants, antihypertensives and antiplatelet therapies). These studies along with several others also exemplify how metabolomics data can complement and inform genetic data in defining ethnic, sex, and gender basis for variation in responses to treatment, which illustrates how pharmacometabolomics and pharmacogenomics are complementary and powerful tools for precision medicine. Conclusions: Key scientific concepts and recommendations for precision medicine Our metabolomics community believes that inclusion of metabolomics data in precision medicine initiatives is timely and will provide an extremely valuable layer of data that compliments and informs other data obtained by these important initiatives. Our Metabolomics Society, through its “Precision Medicine and Pharmacometabolomics Task Group”, with input from our metabolomics community at large, has developed this White Paper where we discuss the value and approaches for including metabolomics data in large precision medicine initiatives. This White Paper offers recommendations for the selection of state of-the-art metabolomics platforms and approaches that offer the widest biochemical coverage, considers critical sample collection and preservation, as well as standardization of measurements, among other important topics. We anticipate that our metabolomics community will have representation in large precision medicine initiatives to provide input with regard to sample acquisition/preservation, selection of optimal omics technologies, and key issues regarding data collection, interpretation, and dissemination. We strongly recommend the collection and biobanking of samples for precision medicine initiatives that will take into consideration needs for large-scale metabolic phenotyping studies.

At present, diagnosis of Ebola virus disease requires transport of venepuncture blood to field biocontainment laboratories for testing by real-time RT-PCR, resulting in delays that complicate patient care and infection control efforts. Therefore, an urgent need exists for a point-of-care rapid diagnostic test for this disease. In this Article, we report the results of a field validation of the Corgenix ReEBOV Antigen Rapid Test kit. We performed the rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebola virus disease presenting at two clinical centres in Sierra Leone. Adults and children who were able to provide verbal consent or assent were included; we excluded patients with haemodynamic instability and those who were unable to cooperate with fingerstick or venous blood draw. Two independent readers scored each rapid diagnostic test, with any disagreements resolved by a third. We compared point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH, Hamburg, Germany) for venepuncture plasma samples tested in a Public Health England field reference laboratory (Port Loko, Sierra Leone). Separately, we performed the rapid diagnostic test (on whole blood) and real-time RT-PCR (on plasma) on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone, including our two clinical centres. In point-of-care testing, all 28 patients who tested positive for Ebola virus disease by RT-PCR were also positive by fingerstick rapid diagnostic test (sensitivity 100% [95% CI 87·7–100]), and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test (specificity 92·2% [95% CI 83·8–97·1]). In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test (sensitivity 100% [95% CI 92·1–100]), and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test (specificity 92·2% [88·0–95·3]). The two independent readers agreed about 95·2% of point-of-care and 98·6% of reference laboratory rapid diagnostic test results. Cycle threshold values ranged from 15·9 to 26·3 (mean 22·6 [SD 2·6]) for the PCR-positive point-of-care cohort and from 17·5 to 26·3 (mean 21·5 [2·7]) for the reference laboratory cohort. Six of 16 banked plasma samples from rapid diagnostic test-positive and altona-negative patients were positive by an alternative real-time RT-PCR assay (the Trombley assay); three (17%) of 18 samples from individuals who were negative by both the rapid diagnostic test and altona test were also positive by Trombley. The ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population (maximum cycle threshold 26·3). With two independent readers, the test detected all patients who were positive for Ebola virus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. Abundance Foundation.

Purpose In adults requiring treatment in an intensive care unit, probiotic therapy using Lactobacillus plantarum 299v may reduce nosocomial infection. The aim of this study was to determine whether early and sustained L. plantarum 299v therapy administered to adult ICU patients increased days alive and at home. Methods A multicentre, parallel group, placebo-controlled, randomised clinical trial was conducted. Adult patients within 48 h of intensive care admission and expected to require intensive care beyond the day after recruitment were eligible to participate. L plantarum 299v or placebo were administered immediately after enrolment and continued for 60 days. The primary outcome was days alive and out of hospital to Day 60 (DAOH 60 ). Secondary outcomes included nosocomial infections. Results The median [interquartile range (IQR)] number of DAOH 60 in the probiotic ( n  = 110) and placebo group ( n  = 108) was 49.5 (IQR 37.0–53.0) and 49.0 (IQR 43.8–53.0) respectively, between-group difference of 0.0 [95% confidence interval (CI) − 6.10 to 7.1, P  = 0.55]. Nosocomial infection occurred in 8 (7.3%) and 5 (4.6%) of the probiotic and placebo group participants, respectively, odds ratio 1.62 (95% CI 0.51–5.10), P  = 0.57. There were no serious, or probiotic-associated adverse events. Conclusion Early and sustained untargeted administration of probiotic therapy with Lactobacillus plantarum 299v to adult patients admitted to the ICU is safe, but not associated with improved patient outcomes.

Sustainable management of coal waste is one of the major environmental concerns for coal mining, whether active or legacy, worldwide. Coal dump deposits demand a large physical area or footprint for disposal of solid waste, change the topography, and generate both pyritic dust and acid rock drainage (ARD) where pyritic coal waste is deposited. The beneficiation of dump deposits or, preferably, of coal waste prior to its dumping can reduce or even eliminate the liabilities related to coal waste management. In this work, dense medium separation studies of coal discards, using heavy liquids, resulted in three pooled fractions from typical South African coal waste discards from the Mpumalanga region for future use: (a) a fraction of low density with increased calorific value; (b) a fraction of intermediate density, rich in ash and acid neutralizing minerals and lower in sulfur; and (c) a fraction of high density, rich in sulfidic minerals including pyrite. The fractions were characterized using particle size analysis, sink-float studies, static tests to predict ARD potential, proximateand ultimate analysis, and gross calorific value. The results showed that approximately 70% of this discard coal is composed of a material of sufficient quality for energy generation in conventional power stations. A pyrite-rich concentrate made up 2% of the total discard mass; comprising more than 45% of the sulfidic mineral present in the feed and displaying no acid neutralizing capacity (ANC). The remaining discard fraction, with intermediate density, presented potential to be used for several ends including soil fabrication, co-disposal or as aggregate material in civil engineering; additional testing to ensure applicability for the selected re-purposing option should be chosen based on proposed use.